Skip NavigationSkip to Content
Return Return to Search Results

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

  1. Author:
    Maldarelli, F.
    Palmer, S.
    King, M. S.
    Wiegand, A.
    Polis, M. A.
    Mican, J. A.
    Kovacs, J. A.
    Davey, R. T.
    Rock-Kress, D.
    Dewar, R.
    Liu, S. Y.
    Metcalf, J. A.
    Rehm, C.
    Brun, S. C.
    Hanna, G. J.
    Kempf, D. J.
    Coffin, J. M.
    Mellors, J. W.

  2. Author Address

    HIV Drug Resistance Program, NCI, Frederick, MD USA. Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL USA. Nalt Inst Allergy & Infect Dis, Lab Immunoregulat, NIH, Bethesda, MD USA. Natl Inst Hlth Clin Ctr, Dept Crit Care, NIH, Bethesda, MD USA. SAIC Frederick, Frederick, MD USA. Univ Pittsburgh, Ctr Med, Div Infect Dis, Pittsburgh, PA USA.;Maldarelli, F, HIV Drug Resistance Program, NCI, Frederick, MD USA.;fmalli@mail.nih.gov
    1. Year: 2007
    2. Date: Apr
  2. Journal: Plos Pathogens
    1. 3
    2. 4
    3. Pages: 484-488
  4. Type of Article: Article
  5. Article Number: e46
  6. ISSN: 1553-7366
  1. Abstract:

    Current antiretroviral therapy is effective in suppressing but not eliminating HIV-1 infection. Understanding the source of viral persistence is essential for developing strategies to eradicate HIV-1 infection. We therefore investigated the level of plasma HIV-1 RNA in patients with viremia suppressed to less than 50-75 copies/ml on standard protease inhibitor- or non-nucleoside reverse transcriptase inhibitor-containing antiretroviral therapy using a new, real-time PCR-based assay for HIV-1 RNA with a limit of detection of one copy of HIV-1 RNA. Single copy assay results revealed that > 80% of patients on initial antiretroviral therapy for 60 wk had persistent viremia of one copy/ml or more with an overall median of 3.1 copies/ml. The level of viremia correlated with pretherapy plasma HIV-1 RNA but not with the specific treatment regimen. Longitudinal studies revealed no significant decline in the level of viremia between 60 and 110 wk of suppressive antiretroviral therapy. These data suggest that the persistent viremia on current antiretroviral therapy is derived, at least in part, from long-lived cells that are infected prior to initiation of therapy.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1371/journal.ppat.0030046
  3. View record in Web of Science®
  4. WOS: 000248510600003

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel